Table 2.
Prevalence of metabolic syndrome among the study population as a whole and distributed by therapeutic group
| Group A n = 8,138 |
Group B n = 9,415 |
Group C n = 6,516 |
All patients n = 24,069 |
|
|---|---|---|---|---|
| Prevalence of metabolic syndrome | 26.4% | 30.7% | 35.0% | 30.4% |
| Fasting glucose ≥ 6.1 mmol/L | 26.0% | 30.3% | 36.2% | 30.5% |
| Triglycerides > 1.7 mmol/L | 23.3% | 23.7% | 27.2% | 24.5% |
| Hypertensiona (raised BP or treatment) | 100.0% | 100.0% | 100.0% | 100.0% |
| HDL-cholesterol | ||||
| <1.04 mmol/L in men | 18.7% | 19.3% | 22.7% | 20.0% |
| <1.30 mmol/L in women | 30.0% | 30.8% | 32.1% | 30.9% |
| Waist circumference | ||||
| >102 cm in men | 44.8% | 45.7% | 51.1% | 46.9% |
| >88 cm in women | 59.5% | 62.4% | 65.0% | 62.2% |
| Number of MS criteria | ||||
| 1 criterion | 39.7% | 36.2% | 32.8% | 36.4% |
| 2 criteria | 33.9% | 33.1% | 32.3% | 33.2% |
| 3 criteria | 17.2% | 19.6% | 21.9% | 19.4% |
| 4 criteria | 7.6% | 8.7% | 10.5% | 8.8% |
| 5 criteria | 1.7% | 2.4% | 2.5% | 2.2% |
a
Hypertension was a criterion for eligibility to the study. This is the reason why this parameter is quoted 100% in all groups.